Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate-to-severe psoriasis: a post hoc analysis from IXORA-PEDS

Dear Editor,

Nail psoriasis (NP) has been proposed as a potential clinical predictor for a more severe disease course in children with psoriasis, but data regarding NP in children are scarce. Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin(IL)-17A, is an EMA and FDA approved treatment for paediatric (≥6 years old) and adult patients with moderate-to-severe psoriasis and provides rapid clinically meaningful improvements in skin, itch and quality of life (QoL) outcomes at week 12. In IXORA-PEDS, a phase III multicentre, double-blind, randomized, placebo-controlled study (NCT03073200), which assessed efficacy and safety of IXE in paediatric patients with moderate-to-severe psoriasis, 50% of patients randomized to IXE at baseline achieved complete clearance (Nail Psoriasis Severity Index [NAPSI] score = 0) in their NP by week 48. This post hoc analysis provides an in-depth analysis of NP in paediatric psoriasis patients from IXORA-PEDS randomly assigned to IXE through week 48. Overall NP severity, nail bed and nail matrix features at baseline, as well as improvements and clearance of NP over time were evaluated.

Patients were stratified based on fingernail involvement (fingernail NAPSI range: 0–80) as having any degree of NP (‘baseline NP’, N = 34), defined as fingernail NAPSI ≥1, and from that, the subgroup of patients with moderate-to-severe NP (‘significant baseline NP’, n = 20/34) defined as fingernail NAPSI ≥16 and ≥4 fingernails involved.5

Consistent with previously published studies,2,6 in IXORA-PEDS, patients with NP were mostly male and had more severe skin disease, including involvement of other difficult-to-treat areas such as palmoplantar and scalp psoriasis (Table 1). Of note, only one patient with significant baseline NP had concomitant psoriatic arthritis. The average percentage improvements in NAPSI score from baseline were comparable in IXE-treated paediatric patients across cohorts, exhibiting an initial rapid change from baseline up to week 24, with further improvements until week 48 (Fig. 1a). These effects were driven by reductions in both nail matrix and nail bed individual scores, with nail matrix changes primarily affecting the nail plate exhibiting a somewhat slower response (Fig. 1b).

Complete clearance in NP, arguably the most important NP treatment goal from both a patient and clinician perspective,7 was observed in 17.6% (n = 6/34) and 15.0% (n = 3/20) of patients with baseline NP and significant baseline NP, respectively, at week 12 (Fig. 1c). Similar to IXE’s dynamics of nail clearance in adults,5 at week 24, the number of patients achieving NAPSI = 0 rapidly increased (50.0%, n = 17/34 vs. 40.0%, n = 8/20) and plateaued through week 48 (50.0%, n = 17/34 vs. 50.0%, n = 10/20) in both cohorts.

Limitations of this post hoc analysis were the lack of a comparator arm and a low sample size, which prevented the evaluation of NP’ impact on young patients’ QoL.

In adults, through both direct and indirect comparisons, IXE has demonstrated rapid and/or long-term efficacy in NP5,8,9 and ranked best among investigated biologics in terms of improvement in nail scores and complete clearance for NP at weeks 24–26, respectively.7,10 Consistent with the data from adult studies, half of paediatric patients upon treatment with IXE achieved complete clearance in their NP irrespective of disease severity at baseline, confirming and extending the efficacy of IXE in NP to the paediatric population. Furthermore, these results demonstrate the efficacy of IXE in improving both nail matrix and nail bed psoriasis.

Overall, the results of this analysis corroborate the demonstrated efficacy of IXE in NP observed in adults8,10 and provide new information to physicians who treat paediatric patients with this burdensome and debilitating disease.

Conflict of interest

M.M.B.S received grants from/was involved in clinical trials from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Leo Pharma and Pfizer. She served as a consultant for Abbvie, Eli Lilly, Janssen, Leo Pharma, Novartis, UCB and Pfizer; fees were paid.

DOI: 10.1111/jdv.17560

References

4 Kroemer C, Wilsmann-Theis D, Gerdes S et al. Drug survival and reasons for drug discontinuation in palmoplantar psoriasis: a retrospective multicenter study. J Dermatol Treat 2019; 30(5): 503–516.
5 Mössner R, Hoff P, Mohr J et al. Successful therapy of palmoplantar pustulosis with etofacitinib–report on three cases. Dermatol Ther 2020; 33(4): e13753.
6 Murakami M, Terui T. Palmoplantar pustulosis: current understanding of disease definition and pathomechanism. J Dermatol Sci 2020; 98(1): 13–19.
7 Mrowietz U, Bachelez H, Burden AD et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PReCISE study. J Am Acad Dermatol 2019; 80(5): 1344–1352.
8 Mrowietz U, Burden AD, Pinter A et al. Spesolimab, an anti-interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase iia, multicenter, double-blind, randomized. Placebo-Controlled Pilot Study. Dermatol Ther (Heidelb) 2021; 11(2): 571–585.
9 Terui T, Kobayashi S, Okubo Y et al. Efficacy and safety of guselkumab, an anti–interleukin-23 monoclonal antibody, for palmoplantar psoriasis: a randomized clinical trial. JAMA Dermatol 2018; 154(3): 309–316.
10 Terui T, Kobayashi S, Okubo Y et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial. JAMA Dermatol 2019; 155(10): 1153–1161.

© 2021 Eli Lilly. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Table 1 Baseline characteristics for paediatric patients without baseline nail psoriasis (NP), those with baseline NP (NAPSI ≥1) and the subgroup of patients with baseline NP that had significant baseline fingernail psoriasis (NAPSI ≥16 and ≥4 fingernails involved)

|                          | Patients without baseline NP | Patients with baseline NP | Subgroup of patients with significant baseline NP† |
|--------------------------|------------------------------|---------------------------|---------------------------------------------------|
|                          | N = 81                       | N = 34                    | n = 20/34                                         |
| Age (years), mean ± SD   | 13.9 ± 3.0                   | 13.2 ± 3.5                | 12.8 ± 3.8                                        |
| Male sex                 | 33 (40.7)                    | 19 (55.9)                 | 15 (75.0)                                         |
| White race               | 69 (86.3)                    | 26 (76.5)                 | 17 (85.0)                                         |
| BMI (kg/m²), mean ± SD   | 23.2 ± 5.8                   | 26.3 ± 8.4                | 24.9 ± 7.2                                        |
| Duration of psoriasis since diagnosis (years), mean ± SD | 5.8 ± 3.6 | 5.2 ± 2.9 | 4.6 ± 3.0 |
| Prior psoriasis treatment |                              |                           |                                                   |
| Non-biologic systemic    | 24 (29.6)                    | 15 (44.1)                 | 9 (45.0)                                          |
| Biologic                 | 4 (4.9)                      | 1 (2.9)                   | 0 (0.0)                                           |
| Phototherapy             | 15 (18.5)                    | 10 (29.4)                 | 6 (30.0)                                          |
| Involved BSA (%), mean ± SD | 26.6 ± 16.7                | 28.4 ± 22.6               | 25.1 ± 21.6                                       |
| sPGA score, mean ± SD    | 3.4 ± 0.6                    | 3.9 ± 0.6                 | 3.9 ± 0.6                                         |
| sPGA – 3                 | 48 (59.3)                    | 9 (26.5)                  | 5 (25.0)                                          |
| sPGA – 4                 | 31 (38.3)                    | 20 (58.8)                 | 12 (60.0)                                         |
| sPGA – 5                 | 2 (2.5)                      | 5 (14.7)                  | 3 (15.0)                                          |
| PASI, mean ± SD          | 18.9 ± 6.6                   | 21.7 ± 9.2                | 21.2 ± 8.4                                        |
| NAPSI (0–80), mean ± SD  | –                            | 33.9 ± 29.5               | 52.0 ± 25.8                                       |
| NAPSI matrix score† (0–40), mean ± SD | –                           | 18.8 ± 11.3               | 24.4 ± 9.3                                        |
| NAPSI bed score† (0–40), mean ± SD | –                           | 15.7 ± 11.4               | 17.8 ± 11.3                                       |
| PSSI, mean ± SD          | 24.7 ± 16.5                  | 33.2 ± 17.1               | 36.3 ± 17.5                                       |
| PPASI, mean ± SD         | 3.9 ± 4.6                    | 10.4 ± 9.5                | 11.6 ± 10.0                                       |
| DLQI, mean ± SD          | 9.6 ± 5.2                    | 8.4 ± 4.2                 | 8.0 ± 3.9                                         |
| Concomitant PsA          | 0 (0.0)                      | 1 (2.9)                   | 1 (5.0)                                           |

Unless otherwise specified, data are presented as n (%).

BMI, body mass index; BSA, body surface area; DLQI, Dermatology Life Quality Index; IXE, ixekizumab; NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Area and Severity Index; PSSI, Psoriasis Scalp Severity Index; sPGA, static Physician Global Assessment.

†Patients with significant baseline NP are included in the cohort of patients with baseline NP. †Fingernails were divided into quadrants, nail matrix assessed by examining features of pitting, leukonychia, red spots in the lunula or crumbling, with a score of 0 for none, and a maximum score of 4, for features in all nail quadrants. ‡Fingernails were evaluated for nail bed features of onycholysis, splinter haemorrhages, subungual hyperkeratosis and oil drop (salmon patch) dyschromia in the same manner as nail matrix features.

directly to the institution. A.R has worked as a consultant or speaker for AbbVie, Bausch Health, Biderma, Celgene, Chema Elektromet, Eli Lilly, Galderma, Janssen, Leo Pharma, Medac, Menlo Therapeutics, Novartis, Pierre-Fabre, Sandoz and Trevi and participated as principal investigator or sub-investigator in clinical trials sponsored by AbbVie, AnaptysBio, Argenx, CellTrion, Drug Delivery Solutions Ltd, Galderma, Genentech, InflaRx, Janssen, Kynab Limited, Leo Pharma, Menlo Therapeutics, MetrioPharm, MSD, Novartis, Pfizer, Trevi, UCB and VielaBio. C.S, C.E.B and E.R are employees of and own stock in Eli Lilly and Company. AP is an Investigator for Anaptysbio, Eli Lilly, Incyte, Janssen, Krystal Bio, Lenus, Regeneron and UCB, a consultant for Abbvie, Abeona, Almirall, Amagena, Anaptysbio, Arena, Bausch, Bristol Myer Squibb, Dermavant, Dermira, Eli Lilly, Exicure, Forte, Leo, Lifemax, Phoenix, Pierre Fabre, Pfizer, Rapt, Regeneron, Sanoﬁ, Sol-Gel, UCB and Venthera, and on the Data Safety Monitoring Board for AbbVie and Galderma.

Funding sources

Eli Lilly and Company (Indianapolis, Indiana, USA) sponsored this study and medical writing (Gerard Sheehan, PhD) for this correspondence.

M.M.B. Seyger,1,7 A. Reich,2,7 C. El Baou,3 C. Schuster,3,4 E. Riedl,3,4 A.S. Paller5
1Department of Dermatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands, 2Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Department of Dermatology, Medical University of Vienna, Vienna, Austria, 5Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Correspondence: M.M.B. Seyger. E-mail: marieke.seyger@radboudumc.nl

References

1 De Jager MEA, Van De Kerkhof PCM, De Jong EMGJ, Seyger MMB. Epidemiology and prescribed treatments in childhood psoriasis: a survey among medical professionals. J Dermatolog Treat 2009; 20: 254–258.

2 Bronckers IMGJ, Bruins FM, van Geel MJ et al. Nail involvement as a predictor of disease severity in paediatric psoriasis: follow-up data from the Dutch childcapture registry. Acta Derm Venereol 2019; 99: 152–157.

3 Paller AS, Seyger MMB, Alejandro Magariños G et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol 2020; 183: 231–241.

4 Griffiths CEM, Reich K, Lebwohl M et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386: 541–551.

5 Wasel N, Thac Th/C223i D, French LE et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, Head-to-Head Study (IXORA-S). Dermatol Ther (Heidelb) 2020; 10: 663–670.

6 Mercy K, Kwasny M, Cordoro KM et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatr Dermatol 2013; 30: 424–428.

7 Reich K, Conrad C, Kristensen LE et al. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. J Dermatolog Treat 2021; 1: 1–9.

8 van de Kerkhof P, Guenther L, Gottlieb AB et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatology Venereol 2017; 31: 477–482.

9 Blauvelt A, Leonardi C, Elewski B et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol 2021; 184: 1047–1058.

10 Huang IH, Wu PC, Yang TH et al. Small molecule inhibitors and biologics in treating nail psoriasis: a systematic review and network meta-analysis. J Am Acad Dermatol 2021; 19: 135–143.

DOI: 10.1111/jdv.17564